We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The National Institutes of Health (NIH) launched two phase 3 trials yesterday, evaluating different types of blood thinners to treat COVID-19 patients. Read More
As long as a safety review of an AstraZeneca COVID-19 trial that’s been paused due to an illness allows the trial to resume, the drugmaker expects to stay on track and submit its vaccine candidate for regulatory approval by the end of the year. Read More
A second government agency, the Biomedical Advanced Research and Development Authority (BARDA), is now scrutinizing contracts awarded to Moderna, examining whether the vaccine maker failed to disclose millions of dollars it got in federally funded awards in several patents and patent applications the firm has filed for its vaccines. Read More
Reports “are incorrect” that a participant in AstraZeneca’s COVID-19 vaccine trial that was paused Tuesday suffered from transverse myelitis, an AstraZeneca spokesperson told FDAnews Wednesday. Read More
AbbVie has signed a collaboration agreement with Chinese biotech I-Mab to develop and commercialize, lemzoparlimab (TJC4), I-Mab’s monoclonal antibody under development for multiple cancers. Read More
AstraZeneca has paused a late-stage trial of its promising COVID-19 vaccine candidate while it evaluates a single UK patient who may have experienced a serious adverse reaction. Read More
Russia’s Ministry of Health granted conditional approval for the vaccine last month, making it the first COVID-19 vaccine approved in the world. Read More
The FDA’s Aug. 23 Emergency Use Authorization (EUA) for convalescent plasma to treat COVID-19 has left hospitals with a choice — give the treatment to individual patients under the EUA or enroll them in clinical trials that will help settle the question of the treatment’s safety and efficacy. Read More